📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. (2021)

First Author: Tweed CD

Attributed to: Tuberculosis Treatment Trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.5588/ijtld.20.0513

PubMed Identifier: 33762075

Publication URI: http://europepmc.org/abstract/MED/33762075

Type: Journal Article/Review

Volume: 25

Parent Publication: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Issue: 4

ISSN: 1027-3719